Ken Griffin Infinity Pharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2023 Aug 14, 2023	SELL	$0.14 - $0.24 $140 - $240	-1,000 Reduced 2.51%	38,900 $8,000
Q1 2023 May 15, 2023	SELL	$0.16 - $0.74 $2,592 - $11,988	-16,200 Reduced 28.88%	39,900 $6,000
Q4 2022 Feb 14, 2023	SELL	$0.46 - $1.21 $4,278 - $11,253	-9,300 Reduced 14.22%	56,100 $31,000
Q3 2022 Nov 14, 2022	SELL	$0.59 - $1.7 $2,006 - $5,780	-3,400 Reduced 4.94%	65,400 $78,000

1.26M

Ticker INFI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 89,277,904
Description
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of met...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.